OncoMatch/Clinical Trials/NCT03900793
Losartan + Sunitinib in Treatment of Osteosarcoma
Is NCT03900793 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Losartan and Sunitinib for osteosarcoma.
Treatment: Losartan · Sunitinib — This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase of the trial, where efficacy of pre-determined dose will be preliminarily assessed.
Check if I qualifyExtracted eligibility criteria
Cancer type
Osteosarcoma
Performance status
ECOG OR KARNOFSKY 0–2
ECOG performance status (≥18 years old) ≤ 2 or Karnofsky performance score (<18 years old) ≥ 50
Prior therapy
Lab requirements
Blood counts
Peripheral absolute neutrophil count (ANC) ≥ 750/mm3; Platelet count ≥ 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment); Hemoglobin ≥ 8 g/dL (with or without transfusion)
Kidney function
Creatinine clearance or radioisotope GFR > 70 mL/min/1.73 m2 OR a serum creatinine based on age/gender
Liver function
Total bilirubin ≤ 1.5 x ULN for age; SGPT (ALT) ≤ 135 U/L (ULN for SGPT is 45 U/L); Serum albumin ≥ 2.8 g/dL
Cardiac function
Current cardiac ejection fraction > 50% by biplane Simpson method on echocardiogram; QTc ≤ 480 ms
Adequate bone marrow function, defined as: Peripheral absolute neutrophil count (ANC) ≥ 750/mm3; Platelet count ≥ 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment); Hemoglobin ≥ 8 g/dL (with or without transfusion) Adequate renal function, defined as: Creatinine clearance or radioisotope GFR > 70 mL/min/1.73 m2 OR a serum creatinine based on age/gender. Adequate hepatic function, defined as: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age; SGPT (ALT) ≤ 135 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L; Serum albumin ≥ 2.8 g/dL Adequate cardiac function, defined as: Current cardiac ejection fraction > 50% by biplane Simpson method on echocardiogram; QTc ≤ 480 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital Los Angeles · Los Angeles, California
- Children's Hospital Colorado · Aurora, Colorado
- University of Colorado Hospital · Aurora, Colorado
- Children's Hospital of Atlanta · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify